Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J. Dore(St Vincent's Hospital Sydney), Thomas Podsadecki(AbbVie (United States)), Brygida Knysz(Wroclaw Medical University), Victoria Aramă(Carol Davila University of Medicine and Pharmacy), Florin Alexandru Căruntu(National Institute of Research and Development for Biological Sciences), Danielle Sullivan(AbbVie (United States)), Joseph Sasadeusz(The Royal Melbourne Hospital), Wayne Ghesquière(Island Health), Adrian Streinu‐Cercel(Université Claude Bernard Lyon 1), Andrew Campbell(AbbVie (United States)), Ewa Janczewska, Alejandro Soza(National Institute of Diabetes and Digestive and Kidney Diseases), Olav Dalgård(Akershus University Hospital), Manuela Curescu, Mudra Kapoor(AbbVie (United States)), Susan Greenbloom, István Tornai(University of Debrecen), Włodzimierz Mazur(Medical University of Silesia), Yan Liu(Qilu Hospital of Shandong University), Xuan Liu(Shanghai University of Traditional Chinese Medicine), Yan Luo(AbbVie (United States)), David Shaw(Royal Adelaide Hospital), Adriana Moţoc(Spitalul Clinic Dr. Victor Babes), Brian Conway, Richard Skoien(Royal Brisbane and Women's Hospital)
Cited by 68
Related Papers
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
|Hepatology|2004|724